CMS121 vs Oxiracetam

N/A

N/A

The Phase 1 trial in healthy volunteers explored single doses up to 1800 mg and repeat doses up to 900 mg/day (young adults) or 600 mg/day (elderly) for 7 days as safety and pharmacokinetics exploration doses, not established therapeutic doses. Pharmacokinetics showed significant age effects (higher exposure in elderly) and food effects (~50% increase in fed state). No validated safe or effective chronic dosing regimen exists for any medical indication. CMS121 is a non-peptide small molecule; some vendors incorrectly label it as a "peptide."

Historical European trials used 400–2400 mg/day (escalating) or 800 mg twice daily under physician supervision as trial protocols, not general safety guidance. In elderly patients given a single 800 mg oral dose, peak serum was ~25±6 µg/mL at 1–3 hours, elimination half-life 3–6 hours, with ~84% recovered unchanged in urine within 24 hours and no accumulation over 7 days of 800 mg twice daily. Drug clearance is reduced in the elderly (AUC approximately doubled versus younger subjects) due to age-related renal decline; renal impairment materially affects elimination. Product identity and purity cannot be assumed from vendor listings; a peer-reviewed 2021 supplement study found oxiracetam claimed on labels but absent from tested products, warranting third-party lab verification.